Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

Novo Nordisk CEO Lars Fruergaard Jorgensen testified before the Senate Health, Education, Labor and Pensions Committee hearing in ...

Novo Nordisk has been criticised by US politicians for the high pricing of its popular weight-loss and diabetes drugs. But ...

CEO Lars Fruergaard Jorgenson has been grilled by a U.S. Senate Committee over the high-cost of the company’s diabetes and ...

Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal ...

Novo Nordisk CEO Lars Fruergaard Jørgensen, however, said that lowering the prices could result in unintended consequences ...

WASHINGTON—U.S. Senator Mike Braun questioned Novo Nordisk CEO, Lars Fruergaard Jørgensen, at the Senate Health, Education, ...

Novo Nordisk's top executive faced a Senate grilling on Tuesday over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars in the ...

The health benefits of blockbuster weight loss drugs are bridging the stark political divide in the United States.

Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today led the committee in a hearing to ...

Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on ...

Novo Nordisk said it’s open to discussions with PBMs based on their commitments that a lower semgalutide list price would not ...